|
As seen from the immune system research, AHCC is a powerful activator of the immune cells and also protects against the side effects induced by chemotherapeutic agents. Since AHCC has no side effects, it has been used in combination with various kinds of treatments such as chemotherapy, radiation, immunotherapies, and anti-inflammatory agent, etc.
1) Fundamental Studies
Dr. Hosokawa et al (Institute for Genetic Medicine, Hokkaido University) conducted a basic study about the use of AHCC in combination with chemotherapy (UFT). When AHCC is administered alongside with UFT treatment, tumor growth and metastasis is suppressed more so than in the UFT only treatment group. (The 4th Symposium of AHCC Research Association, Jun. 1997) （Anti-Cancer Drugs, 1998. 9, 343-350）
Combination of AHCC with GCP, an Anti-Tumor Substance
GCP（Genistein Concentrated Polysaccharide） is a product of soybean isoflavones shown to have anti-angiogenesis activity and apoptosis induction effects. The synergistic effects of GCP and AHCC have been investigated by Amino Up Chemical Co. Ltd. They implanted pulmonary carcinoma cells in mice and gave them either AHCC, GCP, or a combination of AHCC+GCP. Results showed a large synergistic effect from AHCC+GCP treatment after two weeks, as well as induced apoptosis.
(The 92nd American Association for Cancer Research, Mar. 2001).
Combination of AHCC with PMP Antioxidant
PMP（Polyphenolic Mixture of Plant）is a polyphenol mixture produced from buckwheat, which is known for its strong antioxidant activity. Antioxidants can block every step of carcinogenesis such as initiation, promotion, and progression induced by chemical substances. The preventive effects of PMP +AHCC against cancer by inducing skin cancer in test rats via use of a chemical compound have been investigated by Amino Up Chemical Co. Ltd. Results showed there were far more tumors in the control group than in the AHCC + PMP group. （The 2nd Annual Meeting of the Japanese Society for Alternative Medicine & Treatment, Oct. 1999）（The 37th Annual Meeting of the Japanese Society of Cancer Treatment, Oct. 1999）
Clinical Studies
Dr. Kamiyama et al (First Department of Surgery, Kansai Medical University) has studied the prognosis of patients with non-excision pancreatic carcinoma. The control group consisted of patients receiving only chemotherapy and radiation, while the AHCC group received both treatments plus AHCC. Results showed that the AHCC group’s tumor size gradually shrunk, and tumor markers decreased significantly showing an excellent prognosis.
(The 6th Symposium of AHCC Research Association, Nov. 1998)
Dr. Kawaguchi et al (Fujimoto Hospital) used a combination of AHCC and chemotherapy on patients whose tumor could not be removed due to carcinomatous peritonitis, or whose tumor could be removed but were incurable due to liver metastasis. Results showed that chemotherapy alone was not effective on such cases, but combination with AHCC was more effective.
(The 4th Symposium of AHCC Research Association, Jun. 1997)
Combination of AHCC with Low Dose Chemotherapy
Dr. Hosokawa et al (Institute for Genetic Medicine, Hokkaido University) has proposed combination therapy of AHCC and low dose chemotherapy. While low dose anticancer agents cause the release of immunosuppressive substances, which effect cancer cells, AHCC activates and strengthens the immune system. Thus, AHCC works will in combination with low dose anticancer agents to suppress cancer growth, reduce side effects of the drug, and improve QOL. Dr. Hayasaka (Gekakinen Hospital, Sapporo) has investigated this combination in clinical studies. Clinical trials using AHCC and 5-FU, which is one-fifth of usual in stage II breast cancer patient, resulted that the prognosis of these patients improved dramatically after surgery.
Combination of AHCC with Alimentary Therapy
Dr. F. Contreras (Oasis of Hope Hospital, Mexico) investigated the combination of AHCC and alimentary therapy on 18 patients who had already failed conventional therapy such as chemotherapy and radiation. Results showed the combination of AHCC and alimentary therapy lead to a 22% tumor reduction, and 39% tumor stabilization.
(The 6th Symposium of AHCC Research Association, Nov. 1998)
As shown in the fundamental and clinical studies, AHCC has been applied alongside various treatments such as chemotherapy, radiation, alimentary therapy, and other immunotherapy with great success. AHCC has shown to work synergistically with other therapies, enhancing their positive effects, and helping minimize the negative side effects.
| < Previous | Index | ^ TOP ^ | HomePage | Next > |
Copyright © 2000 AHCC Research
Site Maintained By: Data~Creek Creative